Who
Brian Robb Douglass
Chief Product Officer
Company insider
Files Form 4 as: Chief Product Officer, Repligen.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Dec 2025
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —700 at $0.00 | filing |
| 6 Oct 2026filed 8 Oct 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —675 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $42K334 at $126.43 | filing |
| 7 May 2026filed 8 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $42K334 at $126.43 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $28K221 at $124.97 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $28K221 at $124.97 | filing |
| 31 Dec 2025filed 12 Jan 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —2,288 at $0.00 | filing |
| 31 Dec 2025filed 12 Jan 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,143 at $0.00 | filing |
| 31 Dec 2025filed 12 Jan 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,143 at $0.00 | filing |
| 31 Dec 2025filed 12 Jan 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —2,288 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.